Clinical trials: ECT
Nonexudative Age-Related Macular Degeneration, Unspecified Eye, Intermediate Dry Stage
A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration
The purpose of this study is to look at the safety and effectiveness of CNTF implants on vision in participants with atrophic macular degeneration.
- Trial name
- NCT00447954
- Testing
- High Dose NT-501 implant, Low Dose NT-501 implant
- Where
- 8 sites in United States
- Volunteers
- 53 people
- Sponsor
- Neurotech Pharmaceuticals
Hypovolemic Shock
Efficacy of PMZ-2010 (Centhaquine) a Resuscitative Agent for Hypovolemic Shock
This is a prospective, multi-centric, randomized, double-blind, parallel, controlled phase-III efficacy clinical study of PMZ-2010 therapy in patients with hypovolemic shock.
- Trial name
- NCT04045327
- Testing
- Normal saline + Standard Treatment, Centhaquine + Standard Treatment
- Where
- 18 sites in India
- Volunteers
- 105 people
- Sponsor
- Pharmazz, Inc.
Macular Degeneration
Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
Prospective, multi-center 2-stage study. Stage 1 (Phase I) is open-label with all patients treated with the NT-503-3 ECT implant. Stage 1 (Phase I) patients will undergo explantation at year 2.
- Trial name
- NCT02228304
- Testing
- NT-503-3 ECT implantation, Eylea® injected intravitreally administered every 8 weeks
- Where
- 38 sites in United States, Israel
- Volunteers
- 42 people
- Sponsor
- Neurotech Pharmaceuticals
Hypovolemic Shock, Blood Loss
PMZ-2010 (Centhaquine) as a Resuscitative Agent for Hypovolemic Shock
This is a prospective, multi-centric, randomized, double-blind, parallel, controlled phase-II efficacy clinical study of PMZ-2010 therapy in patients with hypovolemic shock. Centhaquine is highly safe and well tolerated.
- Trial name
- NCT04056065
- Testing
- Normal Saline, Centhaquine
- Where
- 7 sites in India
- Volunteers
- 50 people
- Sponsor
- Pharmazz, Inc.
Menorrhagia
Post Approval NovaSure Essure Labeling Study
This post approval, observational study is being conducted to further evaluate the safety of the NovaSure Endometrial Ablation System when it is performed in the presence of Essure micro-inserts.
- Trial name
- PANEL (NCT01934244)
- Testing
- NovaSure Endometrial Ablation
- Where
- 14 sites in United States
- Volunteers
- 318 people
- Sponsor
- Hologic, Inc.
Epilepsy, Rolandic
Safety and Efficacy of Topamax Versus Carbamazepine in Benign Rolandic Epilepsy
The purpose of this study is to determine the efficacy and safety of Topiramate in comparison to Carbamazepine in Benign rolandic epilepsy.
- Trial name
- NCT00216567
- Testing
- topamax
- Volunteers
- 114 people
- Sponsor
- Janssen Korea, Ltd., Korea
Retinitis Pigmentosa
A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa
The purpose of this study is to look at the safety and effectiveness of CNTF implants on vision in persons with retinitis pigmentosa, Usher type II \& III, and Choroideremia.
- Trial name
- NCT00447993
- Testing
- Low Dose NT-501, High Dose NT-501
- Where
- 11 sites in United States
- Volunteers
- 67 people
- Sponsor
- Neurotech Pharmaceuticals
Shock, Hemorrhagic, Shock, Traumatic
Polydatin Injectable (HW6) for Shock Treatment
HW6 can prolong animal's survival time and increase the survival rate. HW6 enhances cardiac function, improves microcirculation, and increases blood pressure and pulse pressure, and improves blood perfusion of important organs…
- Conditions
- Shock, Hemorrhagic, Shock, Traumatic, Shock, Septic
- Trial name
- PIST (NCT01780129)
- Testing
- Polydatin Injectable
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Neptunus Pharmaceuticals Inc.
Retinitis Pigmentosa
A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa
The purpose of this study is to look at the safety and effectiveness of CNTF implants on vision in persons with retinitis pigmentosa, Usher type II \& III, and Choroideremia.
- Trial name
- NCT00447980
- Testing
- NT-501
- Where
- 12 sites in United States
- Volunteers
- 73 people
- Sponsor
- Neurotech Pharmaceuticals